Composition comprising a mixture of molecules extracted from Chrysanthellum indicum, Cynara scolymus and Lycium barbarum and use to act on carbohydrate and/or fat metabolism
Inventors
Peltier, Sebastien • Chavanelle, Vivien • Sirvent, Pascal
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10813965-B2
Publication Date
2020-10-27
Expiration Date
Abstract
A composition comprising at least a mixture of molecules extracted from Chrysanthellum indicum, Cynara scolymus and Lycium barbarum. This composition is in particular useful as a nutritional product or health product to prevent and/or combat fat and/or carbohydrate metabolism disorders in Humans or animals.
Core Innovation
The invention relates to a tablet, capsule or emulsion consisting essentially of a Chrysanthellum indicum extract; a Cynara scolymus extract; a Lycium barbarum extract; an Olea europaea extract; and one or more of synthetic piperine or a piper extract. The composition is described as targeting disorders of fat and carbohydrate metabolism, including dyslipidemia and diabetes-related conditions.
The composition further optionally involves an additional piper component and optionally an Olea europaea extract, and is characterized using extract types such as aqueous, hydroalcoholic, subcritical CO2/H2O extracts. The combination is configured to act synergistically with improved outcomes for lipid parameters, including total cholesterol, LDL cholesterol and triglycerides.
The document reports in vivo mouse data in db/db mice, including effects on total cholesterol, LDL cholesterol, triglycerides, insulin sensitivity, fasting blood glucose, and hepatic triglycerides. The synergy is evaluated using a Colby synergy factor, and the three-plant set is described as providing synergistic cholesterol and LDL outcomes.
Claims Coverage
The independent claim covers a single essential composition for a tablet, capsule or emulsion, defined by four plant extracts plus one or more piperine or piper extract components. Dependent claims expand coverage to additional enumerated nutritional or biologically active constituents and to treating dyslipidemia, obesity, diabetes, and/or hypertension, including optional combination with specified lipopenic and antidiabetic agent classes.
Essential composition with four plant extracts plus piperine
A tablet, capsule or emulsion consisting essentially of a Chrysanthellum indicum extract; a Cynara scolymus extract; a Lycium barbarum extract; an Olea europaea extract; and one or more of synthetic piperine or a piper extract.
Additional nutritional or biologically active constituents under consisting essentially of
The tablet, capsule or emulsion additionally consists essentially of at least one component selected from a listed group including vitamins, organic acids, fatty acids, amino acids or peptides, and various plant or nutritional extracts and biological materials, or mixtures thereof.
Method of treating dyslipidemia, obesity, diabetes, and/or hypertension
A method for treating dyslipidemia, obesity, diabetes, and/or hypertension by administering the tablet, capsule or emulsion to a human in need.
Optional combination with a lipopenic therapeutic agent selected from specified classes
The method further includes administering the tablet, capsule or emulsion in combination with a lipopenic therapeutic agent selected from statins, fibrates, nicotinic acid, ion exchange resins, cholesterol absorption inhibitors, omega 3 polyunsaturated fatty acids, and tiadenol.
Optional combination with antidiabetic agent classes selected under consisting essentially of
The method further consists essentially of metformin, dipeptidyl peptidase-IV inhibitors, glucagon-like peptide-1 analogues, thiazolidinediones, sulfonylureas, acarbose, miglitol, voglibose, and elafibranor.
Overall claim coverage is centered on an essential multiextract composition combined with synthetic piperine and/or a piper extract, with dependents broadening to enumerated additional constituents and therapeutic administration for dyslipidemia, obesity, diabetes, and/or hypertension, including optional co-administration with specified lipopenic and antidiabetic drug classes.
Stated Advantages
Improved lipid outcomes including reductions in total cholesterol and LDL cholesterol and effects on triglycerides.
Improved insulin sensitivity and reduced fasting blood glucose.
Synergistic cholesterol and LDL effects evaluated using a Colby synergy factor.
Decreased hepatic triglycerides with the described combination.
Documented Applications
Use in treating dyslipidemia, obesity, diabetes, and/or hypertension in a human in need.
Use in relation to diabetes-related conditions in db/db mice, including effects on insulin sensitivity, fasting blood glucose, and lipid parameters.
Interested in licensing this patent?